| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 20, 2021 |
| Accession Number: | 0001193125-21-274010 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
SC 13D/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
Soaring Eagle Shareholder Approval Obtained, Closing Scheduled for September 16, 2021 Ginkgo Set to Begin Trading under NYSE: DNA on September 17, 2021 $1.633 billion in proceeds from the business combination represents the largest-ever biotechnology go-public transaction. Investors were led by Baillie Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management). Additional investors included ARK Investment Management LLC, ArrowMark Partners, Bain Capital Public Equity, Cascade Investment, Casdin Capital, Franklin Advisers, T. Rowe Price, and Viking Global Investors. Business combination with Ginkgo approved by Soaring Eagl
BOSTON and ADDIS ABABA, Ethiopia, Sept. 14, 2021 /PRNewswire/ -- The Africa Centres for Disease Control and Prevention (Africa CDC), a specialized technical institution of the African Union, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to bolster the laboratory network capacity for African Union Member States. The partnership is aimed at supporting the continent's public health institutions with appropriate tools, training, and data infrastructure to leverage critical genomic sequencing technologies that will be implemented through Africa CDC Institute for Pathogen Genomics (IPG) and Ginkgo Bioworks. Gin
BOSTON, Sept. 10, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced its readiness to continue scaling support for COVID testing in congregate settings in response to new emergency standards and recommendations issued by the Biden-Harris Administration. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), serves customers across industries seeking to develop new and better products using biology. Last year, Ginkgo launched Concentric by Ginkgo, its public health and biosecurity initiative, to provide a response to the COVID-19 pandemic. Since then, Conc
EFFECT - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
424B3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
BOSTON, Aug. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo"), which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), announced that it will host a presentation reviewing results for the first six months of 2021 after the market closes on Wednesday, August 18, 2021, beginning at 4:30 p.m. ET. The presentation will include an overview of first half performance, recent updates, and a discussion on Ginkgo's business model and outlook. The presentation details and registration link will be available on Ginkgo's investor relation